ArticleBreast cancer research : BCR2026
FBR-NDs: a ferroptosis-inducing nanocomplex for targeted breast cancer therapy via immune modulation and redox-responsive drug delivery.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis in breast cancer: From adipocyte-immune-iron regulation to therapeutic application.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe aim of this study was to develop and characterize a novel ferroptosis-inducing nanocomplex, FBR-NDs (Fe³⁺-BMS-1-R848 Nanodrugs), and to evaluate its anti-tumor effects in breast cancer cells through induction of ferroptosis and modulation of immune responses.
methodsFBR-NDs were synthesized by nanoprecipitation, followed by characterization using transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), and Fourier-transform infrared (FT-IR) spectroscopy to confirm their structure and composition. Drug loading, release, and redox-responsive properties were assessed using ultraviolet-visible spectroscopy, and the drug release profile was evaluated under acidic pH and glutathione (GSH) conditions. In vitro growth inhibition of breast cancer cells (BT549 and MDA-MB-231) was assessed by cell viability, colony formation, and apoptosis assays. Ferroptosis was evaluated by measuring reactive oxygen species (ROS) levels, lipid peroxidation, mitochondrial morphology via electron microscopy, and expression of ferroptosis-related markers. In vivo anti-tumor efficacy was assessed in a 4T1 breast cancer mouse model, and immune responses were evaluated by flow cytometry, immunohistochemistry, and enzyme-linked immunosorbent assays.
resultsFBR-NDs demonstrated high drug loading efficiency and exhibited redox-responsive release behavior under acidic pH and GSH conditions. In vitro, FBR-NDs significantly inhibited breast cancer cell proliferation and induced ferroptosis, as evidenced by elevated ROS levels, lipid peroxidation, and mitochondrial damage. In vivo, FBR-NDs significantly reduced tumor growth, enhanced apoptosis, and induced ferroptosis in tumor tissues. Additionally, FBR-NDs treatment increased the infiltration of immune cells, including dendritic cells (DCs) and M1 macrophages, and promoted T-cell activation. Immunogenic cell death was observed, as evidenced by increased levels of high mobility group box 1 (HMGB1) and calreticulin in tumor tissues.
conclusionFBR-NDs are a promising therapeutic strategy for breast cancer, combining ferroptosis induction with immune modulation. The ability to induce ferroptosis, enhance immune responses, and promote anti-tumor immunity makes FBR-NDs a potential candidate for cancer immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.